Giant cell tumor of the bone of maxillary sinus: A rare uncommon manifestation implicated in a new mosaic of disorders?
DOI:
https://doi.org/10.33448/rsd-v11i14.36499Keywords:
Giant Cell Tumor of Bone; Maxillary Sinus Neoplasms; Head and Neck Neoplasms; Nasal Cavity; Maxilla; Paranasal sinuses.Abstract
The goal is to show a rare case of Giant Cell Tumor of Bone in the maxillary sinus implicated in a process coincidentally or casually with another type of lesion primarily developed. A 33-year-old male patient attended a surgical service, presenting swelling, obstruction and firm mass externalizing through the right nostril and perceived during 6 months. During the anamnesis, the patient stated to been underwent an incisional biopsy 4 years ago of a tumor with histopathological diagnosis of the Nasal Paraganglioma, however the immunohistochemical study was negative for this tumor. During the Computed Tomography evaluate was observed a hyperdense mass occupying the entire maxillary sinus. In the Nuclear Magnetic Resonance evaluation, it was showed a hypersignal image in the entire maxillary sinus, invading the nasal cavity and portion of skull base. A bone window was performed in the right maxillary sinus and excisional biopsy was made. In the new histopathological examination, the diagnose was consistent with Giant Cell Tumor of Bone, being observed a large number of multinucleated giant cells, some with disorganized nuclei and others similar to Touton giant cells. A large proliferation of xanthomatous-looking cells was also observed without features of malignity. At the 3-year follow-up, the patient reported no complications such as facial paralysis, infection, relapse or spread. The association between lesions occurring in the same location requires further study, possibly implicated in a new model of clinical, microscopic, and genetic disorders. Thus, masses originating from chronic inflammatory tissue may have the potential to transform into GCTB?
References
Amary, F., Berisha, F., Ye, H., Gupta, M., Gutteridge, A., Baumhoer, D., & Flanagan, A. M. (2017). H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. The American journal of surgical pathology. 41(8), 1059.
Basu Mallick, A., & Chawla, S. P. (2021). Giant cell tumor of bone: an update. Current Oncology Reports. 23(5), 1-6.
Board WC of TE. Soft Tissue and Bone Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2020.
Brooks, P. J., Glogauer, M., & McCulloch, C. A. (2019). An overview of the derivation and function of multinucleated giant cells and their role in pathologic processes. The American journal of pathology. 189(6), 1145-1158.
Deventer, N., Budny, T., Gosheger, G., Rachbauer, A., Puetzler, J., Theil, J. C., ... & Deventer, N. (2022). Giant cell tumor of bone: A single center study of 115 cases. Journal of bone oncology. 33, 100417.
di Carlo, F. S., Whyte, M. P., & Gianfrancesco, F. (2020). The two faces of giant cell tumor of bone. Cancer Letters. 489, 1-8.
Errani, C., Tsukamoto, S., Leone, G., Righi, A., Akahane, M., Tanaka, Y., & Donati, D. M. (2018). Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. JBJS. 100(6), 496-504.
Kato, I., Furuya, M., Matsuo, K., Kawabata, Y., Tanaka, R., & Ohashi, K. (2018). Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses. Histopathology. 72(6), 914-922.
Kumar, R., Bharani, V., Gupta, N., Gupta, K., Dey, P., Srinivasan, R., & Rajwanshi, A. (2018). Giant cell tumour of tendon sheath: A 10‐year study from a tertiary care centre. Cytopathology. 29(3), 288-293.
Lentini, M., Zuccalà, V., & Fazzari, C. (2010). Polypoid giant cell tumor of the skin. The American journal of dermatopathology. 32(1), 95-98.
Luengo-Alonso, G., Mellado-Romero, M., Shemesh, S., Ramos-Pascua, L., & Pretell-Mazzini, J. (2019). Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Archives of orthopaedic and trauma surgery. 139(10), 1339-1349.
Mohaidat, Z. M., Al-Jamal, H. Z., Bany-Khalaf, A. M., Radaideh, A. M., & Audat, Z. A. (2019). Giant cell tumor of bone: Unusual features of a rare tumor. Rare tumors. 11, 2036361319878894.
Montgomery, C., Couch, C., Emory, C. L., & Nicholas, R. (2019). Giant cell tumor of bone: review of current literature, evaluation, and treatment options. The journal of knee surgery. 32(04), 331-336.
Noh, B. J., & Park, Y. K. (2018). Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. Human pathology. 81, 1-8.
Rosa, D., Dias, R. B., Salvador, J. C., & Borges, A. (2018). Recurrent giant cell tumour of the maxillary sinus and pterygoid process treated with denosumab. Case Reports. 2018, bcr-2018.
Sobti, A., Agrawal, P., Agarwala, S., & Agarwal, M. (2016). Giant cell tumor of bone-an overview. Archives of Bone and Joint Surgery. 4(1), 2.
Tsukamoto, S., Tanaka, Y., Mavrogenis, A. F., Kido, A., Kawaguchi, M., & Errani, C. (2020). Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review. Clinical Orthopaedics and Related Research. 478(5), 1076.
Tuluc, M., Zhang, X., & Inniss, S. (2007). Giant cell tumor of the nasal cavity: case report. European archives of oto-rhino-laryngology. 264(2), 205-208.10
Ud Din, N., Umer, M., & Park, Y. K. (2020). Histomorphometric analysis of pre-and post-denosumab–treated giant cell tumor of bone. International Journal of Surgical Pathology, 28(8), 859-867.
Wülling, M., Engels, C., Jesse, N., Werner, M., Delling, G., & Kaiser, E. (2001). The nature of giant cell tumor of bone. Journal of cancer research and clinical oncology. 127(8), 467-474.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Eliandro de Souza Freitas; Francisco Amadis Batista Ferreira; Milena Gomes Melo Leite; Brendo Vinicius Rodrigues Louredo; Fábio Arruda Bindá; José da Cruz Luna Neto; Caroline Alfaia Silva; Jeconias Câmara
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
